Ivermectin, Fenbendazole, Mebendazole and Niclosamide for Cancer (2026): Mechanisms, Evidence, Precision Oncology and Integrative Strategies

By Editorial Team

In August 2016, Tippens was diagnosed with small cell lung cancer with a fist-sized tumor. Small cell lung cancer (SCLC) is one of the most aggressive cancers known to mankind.

After undergoing chemotherapy and radiation five times a week in Houston, the large tumor in his left lung was eliminated. However, Tippens said the treatments came closer to killing him than curing him.

Joe Tippens never planned to discover a potential remedy that he credits with saving his life and thrust him into the spotlight among notable cancer survivors. The 67-year-old businessman just wanted to beat a type of cancer with an extremely low survival rate.

When he returned home to Oklahoma after the New Year, he received devastating news. His oncologist told him he had zero chance of surviving for more than a few months.

“In January of 2017, my PET scan lit up like a Christmas tree and I had wide metastasis everywhere, including in my neck, bones, pancreas, and liver,” Tippens said.

Facing a prognosis of three months to live, Tippens heard an intriguing story from a veterinarian he knew: A scientist with terminal cancer reportedly cured her lab mice and then herself using fenbendazole, an antiparasitic drug.

The story was the beginning of what eventually became the “Joe Tippens Protocol.”

Note: The Joe Tippens Fenbendazole Cancer Protocol has been gaining rapid interest over the past years following some fenbendazole advanced cancer success stories.

Fenbendazole, used for 30 years to treat intestinal parasites in animals, has not received U.S. Food and Drug Administration (FDA) approval for human use, meaning doctors cannot prescribe it for people. However, with a terminal diagnosis and nothing to lose, Tippens decided to try it alongside his conventional treatments.

Starting in the third week of January 2017, Tippens began taking the fenbendazole, 222 mg per day for three consecutive days per week. After four days without the medication, he would repeat his three-day routine. Three months later, Tippens was cancer-free.

His protocol also included Theracurmin, a form of the active compound in turmeric, and CBD, an extract of cannabis which does not cause intoxication.

Repurposed antiparasitic drugs are becoming one of the most discussed areas in integrative and experimental oncology. Among the most frequently studied are:

  • Ivermectin

  • Fenbendazole

  • Mebendazole

  • Niclosamide

Originally developed to treat parasitic infections, these drugs have demonstrated intriguing anti-cancer effects in laboratory and animal studies. Researchers are now exploring whether they may complement conventional cancer treatments by targeting cancer metabolism, stem cells, immune evasion, and treatment resistance pathways.

However, despite growing enthusiasm online, the clinical evidence in humans remains limited and largely investigational.



This updated 2026 review integrates emerging research, precision oncology concepts, metabolic therapy frameworks, and systems biology perspectives.

Why Repurposed Antiparasitic Drugs Are Gaining Attention in Oncology

Modern cancer biology increasingly recognizes that tumors are not driven by a single mutation alone. Cancer progression often involves:

  • Genetic mutations

  • Epigenetic dysregulation

  • Metabolic reprogramming

  • Chronic inflammation

  • Immune suppression

  • Mitochondrial dysfunction

  • Cancer stem cells

  • Tumor microenvironment signaling

Repurposed drugs are attractive because many appear to affect multiple pathways simultaneously.

Potential advantages include:

  • Low cost

  • Existing safety data

  • Multi-target effects

  • Oral administration

  • Potential synergy with chemotherapy and immunotherapy

This systems-based approach aligns with emerging “network oncology” and precision medicine models.


Ivermectin and Cancer

Ivermectin remains one of the most widely discussed repurposed oncology drugs.

Its anti-cancer interest stems from its broad effects on:

  • Cellular transport systems

  • Stem cell signaling

  • Immune pathways

  • Metabolic regulation

Proposed Anti-Cancer Mechanisms of Ivermectin

1. Importin α/β Nuclear Transport Inhibition

One of ivermectin’s most distinctive mechanisms involves blocking nuclear transport proteins required by several oncogenic transcription factors.

2. Wnt/β-Catenin Suppression

Ivermectin may inhibit Wnt signaling involved in:

  • Stemness

  • Metastasis

  • Resistance pathways

3. AKT/mTOR Inhibition

The AKT/mTOR pathway regulates:

  • Growth

  • Survival

  • Metabolism

  • Autophagy

Ivermectin may suppress this signaling axis in several tumor models.

4. Immunomodulatory Effects

Potential effects include:

  • Enhanced T-cell activation

  • Increased immunogenic cell death

  • Reduced tumor immune suppression

5. Stem Cell Targeting

Like niclosamide, ivermectin may affect cancer stem-like cells linked to relapse and resistance.

Mebendazole and Cancer

Why Mebendazole Has Become a Major Focus

Among all benzimidazole antiparasitic drugs, mebendazole currently has the strongest human oncology research base.

Unlike fenbendazole, mebendazole:

  • Has human approval data

  • Has better pharmacokinetic characterization

  • Crosses the blood-brain barrier

  • Has been investigated in several clinical oncology studies

This has made it a leading candidate in repurposed cancer drug research.

Proposed Anti-Cancer Mechanisms of Mebendazole

1. Microtubule Disruption

Like some chemotherapy drugs, mebendazole interferes with tubulin polymerization, disrupting mitosis and cancer cell division.

This mechanism resembles:

  • Vincristine

  • Vinblastine

  • Paclitaxel

2. Anti-Angiogenesis Effects

Mebendazole may inhibit tumor blood vessel formation by suppressing VEGF signaling.

This may reduce:

  • Tumor growth

  • Nutrient delivery

  • Metastatic potential

3. Cancer Stem Cell Suppression

Emerging research suggests mebendazole may target cancer stem-like cells associated with:

  • Recurrence

  • Metastasis

  • Drug resistance

This is especially relevant in aggressive cancers such as:

  • Glioblastoma

  • Pancreatic cancer

  • Triple-negative breast cancer

4. MAPK and Hedgehog Pathway Effects

Mebendazole may interfere with:

  • Hedgehog signaling

  • ERK/MAPK pathways

These pathways are involved in tumor proliferation and stemness.

5. Immune Modulation

Some studies suggest mebendazole may improve anti-tumor immune activity by:

  • Increasing immune cell infiltration

  • Reducing suppressive tumor signaling

  • Enhancing immunogenic cell death

This has generated interest in combining it with checkpoint inhibitors.

Fenbendazole and Cancer

Fenbendazole belongs to the same benzimidazole family as mebendazole but is primarily a veterinary drug.

Interest surged following anecdotal reports from patients claiming unexpected cancer remissions while using fenbendazole-containing protocols.

However, human oncology data remains far more limited compared with mebendazole.

Proposed Anti-Cancer Mechanisms of Fenbendazole

1. Tubulin Disruption

Fenbendazole disrupts microtubule formation, impairing cancer cell division.

2. Metabolic Stress

Fenbendazole may impair glucose utilization and glycolysis.

This is relevant because many aggressive cancers rely heavily on glucose metabolism.

3. Oxidative Stress Induction

Studies suggest fenbendazole may increase reactive oxygen species (ROS), potentially triggering apoptosis.

4. p53 Activation

Some experimental studies indicate possible activation or stabilization of p53 tumor suppressor pathways.

Niclosamide and Cancer

Why Niclosamide Is Drawing Major Research Interest

Niclosamide, originally developed as an anti-tapeworm medication, has become one of the most promising repurposed metabolic oncology agents.

Unlike many conventional targeted therapies, niclosamide appears to affect multiple cancer survival pathways simultaneously.

Proposed Anti-Cancer Mechanisms of Niclosamide

1. Wnt/β-Catenin Inhibition

Niclosamide is one of the best-known repurposed inhibitors of Wnt/β-catenin signaling.

This pathway is associated with:

  • Cancer stem cells

  • Metastasis

  • Immune evasion

  • Drug resistance

Tumors potentially relevant include:

  • Colorectal cancer

  • Hepatocellular carcinoma

  • Triple-negative breast cancer

2. Mitochondrial Uncoupling

Niclosamide disrupts mitochondrial oxidative phosphorylation.

This may:

  • Reduce ATP production

  • Increase metabolic stress

  • Impair tumor adaptability

This mechanism has increased interest in combining niclosamide with:

  • Ketogenic diets

  • Metabolic therapy

  • Fasting-mimicking strategies

3. STAT3 and NF-κB Suppression

Niclosamide may suppress inflammatory oncogenic signaling pathways linked to:

  • Tumor progression

  • Immune suppression

  • Chemotherapy resistance

4. Cancer Stem Cell Targeting

Some studies suggest niclosamide may reduce stem-cell-like tumor populations associated with recurrence.

5. Potential Immunotherapy Synergy

Emerging research suggests niclosamide may improve tumor immune responsiveness.

This has generated interest in combinations with:

  • Pembrolizumab

  • Nivolumab

  • Other checkpoint inhibitors

Why Combination Protocols Are Receiving Attention

Researchers are increasingly exploring whether combining repurposed drugs may target multiple cancer vulnerabilities simultaneously.

Potential targets include:

  • Glycolysis

  • Mitochondrial metabolism

  • Stem cells

  • Angiogenesis

  • Immune evasion

  • Tumor signaling pathways

Example experimental combinations being discussed include:

  • Mebendazole + ivermectin

  • Niclosamide + immunotherapy

  • Mebendazole + ketogenic diet

  • Ivermectin + checkpoint inhibitors

  • Niclosamide + metabolic therapy

This systems-based approach resembles combination oncology used in HIV and tuberculosis treatment models.

Precision Oncology Integration

One of the biggest developments in 2025–2026 is the integration of repurposed drugs into precision oncology frameworks.

Researchers are beginning to investigate whether certain tumor subtypes may theoretically respond better to specific repurposed agents.

Potential Precision Oncology Associations

Wnt-Driven Tumors

Potentially relevant for:

  • Niclosamide

  • Ivermectin

Possible cancers:

  • Colorectal cancer

  • Liver cancer

  • Triple-negative breast cancer

Highly Glycolytic Tumors

Potentially relevant for:

  • Fenbendazole

  • Niclosamide

Possible cancers:

  • Pancreatic cancer

  • Glioblastoma

  • Aggressive colorectal cancers

Stem-Cell-Rich Tumors

Potentially relevant for:

  • Mebendazole

  • Niclosamide

  • Ivermectin

Immunologically “Cold” Tumors

Potential future interest:

  • Ivermectin combinations

  • Niclosamide combinations

Especially with checkpoint inhibitor therapy.

However, no validated biomarkers currently exist for selecting patients for these repurposed drugs.

What Does the Human Evidence Actually Show?

Strong Preclinical Evidence

Laboratory and animal studies consistently demonstrate:

  • Tumor growth inhibition

  • Apoptosis induction

  • Reduced metastasis

  • Stem cell suppression

  • Enhanced chemotherapy sensitivity

Human Evidence Remains Limited

Current human evidence mainly includes:

  • Case reports

  • Anecdotal reports

  • Retrospective cohorts

  • Small pilot studies

There are still:

  • No large randomized trials

  • No standardized protocols

  • No definitive survival data

As of 2026, these therapies remain experimental in oncology.

Risks and Controversies

Potential Risks

Important concerns include:

  • Delayed standard treatment

  • Drug interactions

  • Liver toxicity

  • Neurotoxicity

  • Unregulated veterinary products

  • Dosing uncertainty

Fenbendazole is especially controversial because it is not approved for human use.

The Social Media Problem

Online communities frequently promote these agents as “hidden cures” or “suppressed treatments.”

This narrative oversimplifies the evidence.

While the science is increasingly interesting, there is still insufficient clinical proof to support replacing standard oncology care with these drugs alone.

The Future: Systems Oncology and Multi-Modal Cancer Therapy

The emerging direction of integrative oncology increasingly involves combining:

  • Precision medicine

  • Metabolic therapy

  • Immunotherapy

  • Repurposed drugs

  • Nutritional interventions

  • Exercise

  • Circadian optimization

  • Microbiome strategies

Repurposed antiparasitic drugs may eventually find a role within broader evidence-based multi-modal protocols.

However, determining:

  • Which patients benefit,

  • Which combinations work best,

  • Optimal dosing,

  • Long-term safety,

  • Biomarker-guided selection,

will require much more clinical research.

Key Takeaways

What We Know

  • Mebendazole currently has the strongest human oncology evidence among benzimidazoles.

  • Niclosamide is emerging as a major metabolic and Wnt-targeting candidate.

  • Ivermectin shows broad multi-pathway anti-cancer activity in preclinical research.

  • Fenbendazole remains highly controversial due to limited human data.

  • Combination strategies are becoming increasingly important.

What We Still Do Not Know

  • Optimal protocols

  • Long-term safety

  • Best cancer subtypes

  • Biomarker selection

  • Survival benefits

  • Most effective combinations

Bottom Line

As of 2026, ivermectin, fenbendazole, mebendazole, and niclosamide remain investigational in oncology.

The mechanistic rationale is compelling and rapidly evolving, particularly within precision oncology and metabolic cancer research. However, robust human clinical evidence remains insufficient.

Patients considering these therapies should do so only with qualified medical supervision and ideally as part of evidence-informed integrative oncology strategies rather than as replacements for established cancer treatments.

Comments

Post a Comment

Popular posts from this blog

Ivermectin for Cancer Treatment: Protocols and Evidence (2026 Update)

By Editorial Team
Image
Ivermectin is a drug primarily used to treat parasitic infections, and it has attracted research interest for its potential biological effects in cancer models, particularly within integrative and experimental treatment contexts. However, current mainstream oncology guidelines do not support ivermectin as a standard or evidence-based treatment for cancer, especially as a substitute for established therapies such as immunotherapy, targeted therapy, chemotherapy, or radiation. Access to modern cancer care also remains uneven globally. Advanced diagnostic testing, molecular profiling, and novel therapies are often more accessible in high-income healthcare systems or through comprehensive insurance coverage. In contrast, patients in lower-resource or impoverished settings may face significant barriers to timely diagnosis and access to cutting-edge treatments. In this context, repurposed drugs—including ivermectin—are sometimes discussed in research and public discourse due to their low c...
Read more

Fenbendazole and the Joe Tippens Protocol: Evidence, Risks, and Current Perspective (2026 Update)

By Editorial Team
Image
Introduction The Joe Tippens Protocol revolves around the off-label use of fenbendazole (a veterinary dewormer commonly sold as Panacur C or Safe-Guard) combined with various supplements for cancer. The Protocol has been gaining rapid interest over the past years following some  fenbendazole advanced cancer success stories . Joe Tippens popularized this approach after claiming it contributed to his remission from metastatic small-cell lung cancer in 2017. As of 2026, Joe Tippens remains alive and reports being cancer-free for over 8 years, continuing a maintenance version of the protocol. Fenbendazole is marketed for animals (e.g., Panacur C, Safe-Guard ) and has no regulatory approval for human cancer treatment . Evidence for anticancer effects is primarily preclinical or anecdotal , and clinical trials in humans are lacking. Important Disclaimer: Fenbendazole is not approved by the FDA, EMA, or any regulatory body for human use or canc...
Read more

Fenbendazole and Ivermectin for Cancer: A Case Series of Over 700 Patients (2026)

By Editorial Team
Image
Anecdotal reports and preliminary studies suggest that ivermectin and fenbendazole, both antiparasitic drugs, may have potential anticancer effects when used alongside other treatments.  Many people immediately dismiss the potential of ivermectin and fenbendazole when they learn it is “horse or dog medicine”. That initial reaction is overcome when genuine human success stories are told including the lack of serious side effects. The testimonials you are about to read are from individuals who have bravely shared their experiences in the hope of inspiring and uplifting others. These are raw human accounts, unfiltered by gatekeepers—not peer-reviewed studies—but they offer insights that may be valuable to those searching for options. However, we acknowledge that robust clinical trials are needed to provide more conclusive scientific evidence. Contents: Editor's Preface Introduction Fenbendazole and Ivermectin Case Series Compilation (alphabetical) Breast Cancer Success Stories  (...
Read more

Top 10 Cancer Fighting Supplements: Evidence Based Literature Review (2026 Update)

By Editorial Team
Image
Are you overwhelmed by conflicting advice on cancer, diet, and supplements ? You’re not alone. With so many claims out there, it’s hard to separate fact from fiction . Can certain foods lower your cancer risk ? Are some foods increasing it without you realizing? What about vitamin and mineral supplements —do they help prevent cancer, or could they actually increase your risk ? The term " anti-cancer supplements " can be misleading. While some nutrients support the body in cancer prevention or treatment, others may interfere with therapies or even pose risks. There are presently over 1,500 herbs and food supplements in commerce, many of them with claims in use against cancer. This guide compiles over 500 scientific r...
Read more

Exploring Ivermectin, Mebendazole and Fenbendazole as Aggressive Cancer Treatments: Research, Protocols, and Controversies (2025)

By Editorial Team
Image
Fenbendazole and ivermectin, both antiparasitic drugs that have shown potential in cancer treatment through several mechanisms, such as slowing cancer cell growth and boosting the immune response. Fenbendazole is being studied for its ability to disrupt energy production in cancer cells, effectively hindering their growth. Ivermectin, on the other hand, has been explored in combination with checkpoint inhibitors to boost the immune system's response to tumors—especially in challenging cases like triple-negative breast cancer. Introduction Cancer remains a leading cause of morbidity and mortality worldwide, with an increasing incidence of aggressive and treatment-resistant tumors such as triple-negative breast cancer (TNBC), pancreatic adenocarcinoma, and glioblastoma. Despite significant advances in targeted therapies and immunotherapies, many patients continue to face limited effective options, highlighting an urgent need for novel, affordable, and accessible treatment strategies....
Read more

Fact Check: Can Ivermectin and Fenbendazole Help Treat Cancer?

By Editorial Team
Image
Ivermectin and fenbendazole, originally developed as antiparasitic drugs, are sparking hope in the fight against cancer, fueled by inspiring stories like those shared by actor  Mel Gibson on The Joe Rogan Experience , where he celebrated friends’ remarkable recoveries. While these medications aren’t yet standard cancer treatments, early research is uncovering exciting potential. Scientists are encouraged by promising lab studies and are calling for more clinical trials to confirm their effectiveness and ensure safe use in humans, paving the way for innovative, accessible therapies that could transform lives. Introduction and Context According to a January 22, 2025 fact-check article by AFP: "The anti-parasitic drugs ivermectin and fenbendazole are not currently recommended for cancer, but posts spread across social media touting the medications after actor  Mel Gibson claimed on the Joe Rogan Experience  that they cured his friends' cases of the disease. Oncology ex...
Read more

Fenbendazole vs Ivermectin for Cancer: Differences and Which Is Better?

By Editorial Team
Image
Cancer patients are increasingly inquiring about the use of the anthelmintic drugs Fenbendazole (FenBen) and Ivermectin (IVM) as potential treatments for cancer. Notably, these patients typically fall into two distinct groups, neither of which represents the usual stage 1 or 2 cancer cases where conventional therapies often show promise. The first group consists of older men whose lung or prostate cancer has recurred. Having undergone conventional treatments previously without success, they express skepticism about its effectiveness this time around. The second, larger group comprises younger patients under 40 dealing with aggressive breast cancer, colorectal cancer, or lymphoma—forms of early-onset cancers that appear to lack the typical mutations observed in traditional cases. This article aims to delve into the differences between Fenbendazole and Ivermectin by examining their me...
Read more

Fenbendazole and Cancer: What the Science Really Shows (Evidence, Risks & Open Questions)

By Editorial Team
Image
Abstract Background:  Fenbendazole (FBZ), a benzimidazole anthelmintic approved for veterinary use, has attracted attention for potential anticancer activity based on laboratory findings and widespread anecdotal reports.  Objective:  To critically appraise the current evidence on fenbendazole and cancer using a peer‑review style framework.  Methods:  Narrative review of preclinical studies, publicly reported human case narratives, and safety signals, with emphasis on evidence hierarchy and translational limitations.  Results:  Preclinical data demonstrate antiproliferative effects via microtubule disruption and metabolic stress in vitro and in animal models. Human evidence is limited to uncontrolled case reports; no Phase I–III clinical trials or regulatory approvals for oncology exist. Safety data in humans are sparse, with hepatotoxicity signals reported.  Conclusions:  Fenben...
Read more

Dr. William Makis's Recommended Ivermectin Dosages for Cancer (2026)

By Editorial Team
Image
Dr. William Makis, a radiologist and cancer researcher, has developed a "hybrid orthomolecular" protocol that incorporates ivermectin as a repurposed drug for cancer treatment. This approach targets cancer stem cells and mitochondrial dysfunction, often in combination with other therapies like benzimidazoles (e.g., mebendazole or fenbendazole), vitamins, and dietary changes. The protocol is based on preclinical studies, case reports, and his clinical observations, but it remains experimental and unapproved by regulatory bodies like the FDA for cancer use. Dosages are weight-based (e.g., for a 70 kg/154 lb person, 1 mg/kg = 70 mg) and stratified by cancer severity: low-grade (early-stage or slow-growing), intermediate-grade (moderately progressive), or high-grade (aggressive, metastatic, or "turbo" cancers). Always consult a healthcare provider for personalization, monitoring (e.g., liver/kidney function), and integration with conventional treatments. Key Ivermectin...
Read more

2025 Study: Ivermectin and Balstilimab for Stage 4 Triple Negative Breast Cancer - Cedars-Sinai Medical Center Study

By Editorial Team
Image
Authors: Yuan Yuan, Jin Sun Bitar, MaLia Walker, David Lin, January Lee, So Yung Choi, Stephen Shiao, Mourad Tighiouart, Paul H. Frankel, Peter P. Lee Affiliation: Cedars-Sinai Medical Center, Los Angeles, CA Abstract e13146 (2025 ASCO Annual Meeting) is a phase 1/2 study of ivermectin in combination with balstilimab after 1-2 prior lines of therapy for triple negative breast cancer ( J Clin Oncol 2025 ) Background: Despite recent FDA approval of immune checkpoint inhibitor (ICI) and antibody-drug conjugates (ADCs), therapeutic options for metastatic triple negative breast cancer (mTNBC) remain limited. Preclinical data showed that ivermectin induces robust T cell infiltration into breast tumors and turning “cold” tumors “hot” in mouse model of TNBC. Balstilimab is a fully humanized IgG4 anti-PD-1 agent with proven safety and efficacy in metastatic cervical cancer. The current phase I/II trial is designed to test the safety and efficacy of the combination of ivermectin and balsti...
Read more

Archive

Show more